See more : Laurentian Bank of Canada (LB.TO) Income Statement Analysis – Financial Results
Complete financial analysis of GNI Group Ltd. (2160.T) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of GNI Group Ltd., a leading company in the Biotechnology industry within the Healthcare sector.
- LIKE Co., Ltd. (2462.T) Income Statement Analysis – Financial Results
- Motilal Oswal Financial Services Limited (MOTILALOFS.BO) Income Statement Analysis – Financial Results
- UOMO Media Inc. (UOMO) Income Statement Analysis – Financial Results
- Aoyama Zaisan Networks Company,Limited (8929.T) Income Statement Analysis – Financial Results
- Shandong Hongyu Agricultural Machinery Co., Ltd. (002890.SZ) Income Statement Analysis – Financial Results
GNI Group Ltd. (2160.T)
About GNI Group Ltd.
GNI Group Ltd. engages in the research, development, manufacture, and sale of pharmaceutical drugs and traditional Chinese medicines in Japan and internationally. It provides Etuary for the treatment of idiopathic pulmonary fibrosis. The company is also developing Etuary, which is in Phase III clinical trial for the treatment of connective tissue associated interstitial lung disease; and in clinical trial phase II and pre-phase III clinical trial pilot study for the treatment of radiation pneumonitis, as well as for the treatment of diabetic nephropathy. In addition, it is involved in developing F351, which is in Phase II clinical trial for the treatment of liver fibrosis; and F573 that is in pre-clinical phase for the treatment of acute on chronic liver failure, as well as Tamibarotene for the treatment of acute promyelocytic leukemia. GNI Group Ltd. was incorporated in 2001 and is headquartered in Tokyo, Japan.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2008 | 2007 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 26.01B | 17.42B | 12.69B | 9.77B | 7.45B | 5.02B | 2.65B | 1.31B | 1.02B | 474.72M | 183.60M | 161.94M | 90.33M | 272.88M | 204.35M | 273.59M |
| Cost of Revenue | 3.58B | 2.67B | 1.60B | 1.55B | 1.05B | 848.27M | 494.99M | 189.68M | 240.95M | 161.17M | 166.35M | 127.33M | 72.44M | 61.87M | 172.20M | 171.79M |
| Gross Profit | 22.43B | 14.74B | 11.09B | 8.23B | 6.40B | 4.17B | 2.15B | 1.12B | 775.72M | 313.55M | 17.25M | 34.61M | 17.89M | 211.01M | 32.15M | 101.80M |
| Gross Profit Ratio | 86.24% | 84.65% | 87.39% | 84.18% | 85.89% | 83.10% | 81.31% | 85.49% | 76.30% | 66.05% | 9.39% | 21.37% | 19.81% | 77.33% | 15.73% | 37.21% |
| Research & Development | 2.56B | 2.55B | 2.02B | 1.24B | 758.13M | 530.25M | 268.57M | 274.27M | 379.10M | 139.00M | 427.00M | 101.00M | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 15.29B | 10.97B | 7.96B | 5.18B | 4.33B | 3.00B | 1.74B | 1.12B | 1.05B | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 839.00K | 3.63B | 2.65B | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 15.29B | 10.97B | 7.96B | 5.18B | 4.33B | 3.00B | 1.74B | 1.12B | 1.05B | 715.00M | 367.00M | 331.00M | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Expenses | -8.53B | -144.50M | -509.73M | -65.50M | 236.00K | 72.86M | -9.44M | 371.00K | -19.87M | 16.90M | 20.10M | 881.00K | 6.57M | 3.11M | 9.36M | 8.72M |
| Operating Expenses | 9.32B | 13.37B | 9.46B | 6.36B | 5.09B | 3.60B | 2.00B | 1.39B | 1.41B | 864.22M | 802.40M | 499.17M | 475.19M | 480.04M | 981.58M | 1.39B |
| Cost & Expenses | 12.90B | 16.04B | 11.07B | 7.90B | 6.14B | 4.45B | 2.49B | 1.58B | 1.65B | 1.03B | 968.75M | 626.50M | 547.63M | 541.90M | 1.15B | 1.56B |
| Interest Income | 771.53M | 259.84M | 129.96M | 46.07M | 39.23M | 21.98M | 51.12M | 19.01M | 27.80M | 5.15M | 1.14M | 522.00K | 468.00K | 858.00K | 2.92M | 5.31M |
| Interest Expense | 1.25B | 869.89M | 647.90M | 109.70M | 144.10M | 225.88M | 34.30M | 128.35M | 44.28M | 11.03M | 9.50M | 9.51M | 1.73M | 2.90M | 3.27M | 4.40M |
| Depreciation & Amortization | 608.42M | 521.67M | 383.03M | 329.61M | 236.75M | 153.57M | 89.61M | 65.83M | 61.16M | 43.55M | 36.07M | 99.48M | 97.93M | 121.00M | 214.90M | 185.97M |
| EBITDA | 14.49B | 2.16B | 2.14B | 2.19B | 1.50B | 557.39M | 261.03M | -191.20M | -585.69M | -241.95M | -740.29M | -435.72M | -359.50M | -135.88M | -754.50M | -1.09B |
| EBITDA Ratio | 55.70% | 12.40% | 16.85% | 22.97% | 21.20% | 14.83% | 9.86% | -14.63% | -55.49% | -81.35% | -400.84% | -231.94% | -403.20% | -56.54% | -369.23% | -398.08% |
| Operating Income | 13.11B | 1.38B | 1.62B | 1.87B | 1.30B | 568.60M | 154.21M | -276.36M | -633.17M | -550.68M | -785.15M | -464.56M | -457.29M | -269.03M | -949.43M | -1.29B |
| Operating Income Ratio | 50.40% | 7.91% | 12.80% | 19.13% | 17.49% | 11.33% | 5.82% | -21.15% | -62.28% | -116.00% | -427.64% | -286.87% | -506.24% | -98.59% | -464.62% | -469.70% |
| Total Other Income/Expenses | -496.10M | -610.05M | -517.94M | -63.63M | -104.86M | -203.90M | -17.08M | -109.34M | -36.46M | 264.82M | -713.00K | -80.16M | -1.86M | 12.15M | -415.08M | 4.66M |
| Income Before Tax | 12.61B | 767.89M | 1.11B | 1.81B | 1.20B | 364.70M | 137.13M | -385.38M | -669.62M | -294.41M | -785.86M | -544.72M | -459.16M | -256.88M | -1.36B | -1.28B |
| Income Before Tax Ratio | 48.49% | 4.41% | 8.72% | 18.48% | 16.08% | 7.27% | 5.18% | -29.49% | -65.86% | -62.02% | -428.03% | -336.36% | -508.30% | -94.14% | -667.74% | -468.00% |
| Income Tax Expense | 3.11B | 1.64B | 1.05B | 440.01M | 567.57M | 172.52M | 108.92M | 80.31M | -1.07M | 2.12M | 46.21M | 1.21M | 1.21M | 1.21M | 1.88M | 2.40M |
| Net Income | 8.09B | -868.25M | 55.24M | 1.26B | 629.92M | 192.17M | -175.21M | -513.10M | -623.15M | -327.95M | -730.78M | -482.26M | -435.45M | -258.09M | -1.37B | -1.28B |
| Net Income Ratio | 31.12% | -4.98% | 0.44% | 12.87% | 8.46% | 3.83% | -6.62% | -39.26% | -61.29% | -69.08% | -398.03% | -297.79% | -482.06% | -94.58% | -668.66% | -467.66% |
| EPS | 169.50 | -18.29 | 1.18 | 28.96 | 14.91 | 4.74 | -4.66 | -15.03 | -18.29 | -9.71 | -23.85 | -16.15 | -16.07 | -9.61 | -62.52 | -63.92 |
| EPS Diluted | 165.56 | -18.11 | 1.14 | 28.04 | 14.45 | 4.74 | -4.66 | -15.03 | -17.87 | -9.47 | -23.85 | -16.15 | -16.07 | -9.61 | -62.52 | -63.92 |
| Weighted Avg Shares Out | 47.75M | 47.47M | 46.92M | 43.44M | 42.26M | 40.50M | 37.63M | 34.13M | 34.06M | 33.77M | 30.64M | 29.86M | 27.09M | 26.85M | 21.86M | 20.02M |
| Weighted Avg Shares Out (Dil) | 48.89M | 47.93M | 48.29M | 44.87M | 43.59M | 40.50M | 37.63M | 34.13M | 34.86M | 34.62M | 30.64M | 29.86M | 27.09M | 26.85M | 21.86M | 20.02M |
Source: https://incomestatements.info
Category: Stock Reports